| | Subgroup | Eligible Studies
(number) | Acupuncture group
(number) | Medication group
(number) | RR/MD (95% CI) | value | Heterogeneity test | Effect model |
| | Acupuncture method | | | | | | | | | Manual acupuncture | 7 [28, 30, 31, 33–37] | 355 | 316 | 1.23 (1.15, 1.32) | | | Fixed | | Electroacupuncture | 2 [29, 34] | 82 | 81 | 1.42 (1.09, 1.85) | | | Random | | Warm needle moxibustion | 1 [32] | 50 | 50 | 1.21 (1.02, 1.44) | | — | — |
| | Intervention type for treatment group | | | | | | | | | Acupuncture | 8 [28, 31–37] | 384 | 364 | 1.25 (1.18, 1.34) | | | Fixed | | Acupuncture + drug | 2 [29, 30] | 83 | 83 | 1.32 (1.14, 1.52) | | | Fixed |
| | Drug categories of control group | | | | | | | | | Ligustrazine | 2 [28, 36] | 124 | 110 | 1.19 (1.06, 1.33) | | | Fixed | | Betahistine | 2 [32, 35] | 83 | 82 | 1.23 (1.07, 1.41) | | | Fixed | | Ligustrazine + flunarizine | 1 [29] | 35 | 35 | 1.26 (1.04, 1.52) | | — | — | | Betahistine + flunarizine | 2 [31, 34] | 111 | 96 | 1.37 (0.99, 1.90) | | | Random | | Nimesulide + eperisone + flunarizine | 1 [33] | 50 | 50 | 1.17 (1.03, 1.33) | | — | — | | Nimodipine | 1 [30] | 48 | 48 | 1.36 (1.11, 1.67) | | — | — | | Traditional Chinese medicine | 1 [37] | 35 | 35 | 1.26 (1.04, 1.52) | | — | — |
|
|
